Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Doxycycline shows promise in cancer therapy, but its molecular mechanisms remain unclear.
• Previous research identified proteinase-activated receptor 1 (PAR1) as a direct target of doxycycline, suppressing tumor progression.
• MicroRNAs (miRNAs) are implicated in the anti-tumor effects mediated by PAR1 and doxycycline.

Purpose of the Study:

• To investigate the role of microRNAs in doxycycline's anti-cancer effects.
• To elucidate the mechanism by which miR-17 influences breast cancer progression and its interaction with doxycycline.

Main Methods:

• In vivo and in vitro experiments to assess miR-17's effect on breast cancer cell metastasis.
• Luciferase and chromatin immunoprecipitation assays to determine the binding of nuclear factor-kappaB (NF-κB) to miR-17 promoters.
• Identification of E-cadherin as a target gene of miR-17.

Main Results:

• miR-17 was identified as a key miRNA promoting breast cancer cell metastasis.
• miR-17 was found to partially reverse the anti-cancer effects of doxycycline.
• NF-κB was confirmed to bind miR-17 promoters, and E-cadherin was identified as a direct miR-17 target gene.

Conclusions:

• miR-17 promotes breast cancer metastasis by targeting E-cadherin.
• miR-17 can counteract doxycycline's inhibitory effects on epithelial-mesenchymal transformation (EMT) in breast cancer.
• Understanding the miR-17/E-cadherin axis provides insights into doxycycline resistance mechanisms in cancer therapy.